Published in Nat Med on October 14, 2012
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. Cancer Res (2014) 0.94
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia (2014) 0.93
Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget (2015) 0.91
Reliable quantification of protein expression and cellular localization in histological sections. PLoS One (2014) 0.89
The global landscape of intron retentions in lung adenocarcinoma. BMC Med Genomics (2014) 0.88
B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One (2014) 0.88
Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J Pathol (2015) 0.85
AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. Oncotarget (2015) 0.83
Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Neoplasia (2013) 0.83
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. Curr Opin Hematol (2013) 0.82
Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1. Leukemia (2015) 0.82
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. Leukemia (2014) 0.81
PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. PLoS One (2014) 0.80
A three-signal model of T-cell lymphoma pathogenesis. Am J Hematol (2015) 0.78
Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun (2016) 0.78
Cleavage of the JunB transcription factor by caspases generates a carboxyl-terminal fragment that inhibits activator protein-1 transcriptional activity. J Biol Chem (2013) 0.76
JunB and PTEN in prostate cancer: 'loss is nothing else than change'. Cell Death Differ (2015) 0.76
Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation. Proc Natl Acad Sci U S A (2016) 0.76
Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct (2015) 0.76
[Blockade of the PDGF receptor: a new and effective therapy option for NPM-ALK-dependent lymphoma]. Pathologe (2014) 0.75
Translational hematology. Wien Med Wochenschr (2014) 0.75
The human genome browser at UCSC. Genome Res (2002) 168.23
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol (2011) 16.53
MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics (2005) 11.75
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science (1994) 10.45
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res (2004) 4.53
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood (2000) 3.99
Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. Nat Immunol (2001) 3.89
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res (2002) 2.70
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood (2009) 2.43
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J (2002) 2.15
The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood (2005) 2.14
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J (2002) 2.00
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest (2007) 1.97
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood (2002) 1.87
Crizotinib in anaplastic large-cell lymphoma. N Engl J Med (2011) 1.79
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol (2004) 1.77
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma (2008) 1.63
Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia (2009) 1.33
Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. J Clin Oncol (2010) 1.31
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood (2006) 1.22
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci U S A (2009) 1.20
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood (2007) 1.18
Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood (2004) 1.17
Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann Oncol (1994) 1.05
Signal transduction by the PDGF receptors. Prog Growth Factor Res (1994) 0.98
A novel role for IL-22R1 as a driver of inflammation. Blood (2010) 0.98
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther (2011) 0.97
Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy. J Clin Oncol (1994) 0.96
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer (2011) 0.93
Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol (2001) 0.82
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J Med Chem (2006) 0.81
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Cerebral organoids model human brain development and microcephaly. Nature (2013) 9.07
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol (2006) 8.53
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
Mitogen-activated protein kinases in apoptosis regulation. Oncogene (2004) 4.76
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell (2006) 4.48
Cancer epigenetics: modifications, screening, and therapy. Annu Rev Med (2008) 4.41
Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A (2004) 4.39
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell (2002) 4.35
Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc Natl Acad Sci U S A (2008) 4.20
The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol (2007) 4.12
Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature (2006) 4.09
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82
p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol (2002) 3.80
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med (2005) 3.68
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Identifying the MAGUK protein Carma-1 as a central regulator of humoral immune responses and atopy by genome-wide mouse mutagenesis. Immunity (2003) 3.36
RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol (2001) 3.27
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med (2005) 3.26
The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell (2013) 3.19
p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet (2007) 3.19
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1. Nat Cell Biol (2006) 3.19
Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell (2007) 3.15
Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature (2005) 3.09
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature (2005) 3.09
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A (2008) 2.99
Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry (2009) 2.95
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med (2007) 2.91
Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. Cell (2010) 2.91
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol (2004) 2.90
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol (2004) 2.90
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol (2011) 2.87
The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity (2008) 2.81
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity (2004) 2.76
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A (2010) 2.72
Forward and reverse genetics through derivation of haploid mouse embryonic stem cells. Cell Stem Cell (2011) 2.69
Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest (2006) 2.68
Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest (2003) 2.68
The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity (2003) 2.67
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
Fos/AP-1 proteins in bone and the immune system. Immunol Rev (2005) 2.58
The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity (2008) 2.57
SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell (2009) 2.57
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood (2002) 2.57
ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature (2012) 2.53
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A (2007) 2.51
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Mitochondrial phosphate-carrier deficiency: a novel disorder of oxidative phosphorylation. Am J Hum Genet (2007) 2.48
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Genome-wide RNAi screen identifies genes involved in intestinal pathogenic bacterial infection. Science (2009) 2.47
Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47
T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med (2006) 2.38
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell (2010) 2.37
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 2.36
Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. Mol Cell Biol (2009) 2.34
Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology (2011) 2.33
Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci (2002) 2.32
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol (2011) 2.29
Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol Cell Biol (2006) 2.28
A global in vivo Drosophila RNAi screen identifies NOT3 as a conserved regulator of heart function. Cell (2010) 2.27
Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell (2005) 2.26